NASDAQ:GMDA - Gamida Cell Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $20.25
  • Forecasted Upside: 174.39 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$7.38
▲ +0.11 (1.51%)
1 month | 3 months | 12 months
Get New Gamida Cell Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GMDA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GMDA

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$20.25
▲ +174.39% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Gamida Cell in the last 3 months. The average price target is $20.25, with a high forecast of $27.00 and a low forecast of $14.00. The average price target represents a 174.39% upside from the last price of $7.38.
Buy
The current consensus among 5 contributing investment analysts is to buy stock in Gamida Cell. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/29/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/27/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/26/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/25/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/23/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/21/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/22/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/21/2021

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/15/2021Needham & Company LLCLower Price TargetBuy$17.00 ➝ $14.00N/A
i
3/9/2021Piper SandlerLower Price Target$25.00 ➝ $23.00Medium
i
3/9/2021Needham & Company LLCLower Price TargetBuy$17.00 ➝ $14.00Low
i
2/10/2021HC WainwrightBoost Price TargetPositive ➝ Buy$15.00 ➝ $27.00Low
i
2/9/2021OppenheimerReiterated RatingBuy$17.00Low
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
12/14/2020OppenheimerLower Price TargetOutperform$20.00 ➝ $17.00Medium
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
12/6/2020OppenheimerInitiated CoverageBuy$20.00High
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
10/6/2020OppenheimerReiterated RatingBuy$20.00High
i
9/24/2020OppenheimerReiterated RatingBuy$20.00Low
i
9/24/2020Needham & Company LLCReiterated RatingBuy$17.00Low
i
Rating by Chad Messer at Needham & Company LLC
8/13/2020HC WainwrightReiterated RatingBuyHigh
i
Rating by V. Bernardino at HC Wainwright
8/11/2020Needham & Company LLCInitiated CoverageBuy$17.00High
i
Rating by Chad Messer at Needham & Company LLC
6/30/2020Evercore ISIInitiated CoverageOutperformHigh
i
5/25/2020Piper SandlerInitiated CoverageOverweight$13.00High
i
5/21/2020Needham & Company LLCLower Price TargetBuy$19.00 ➝ $17.00High
i
Rating by Chad Messer at Needham & Company LLC
5/12/2020Needham & Company LLCReiterated RatingBuy$19.00High
i
5/12/2020OppenheimerBoost Price TargetOutperform$18.00 ➝ $20.00High
i
4/27/2020HC WainwrightInitiated CoverageBuy$15.00High
i
Rating by V. Bernardino at HC Wainwright
2/26/2020BMO Capital MarketsLower Price TargetOutperform$19.00 ➝ $17.00Low
i
12/10/2019Needham & Company LLCReiterated RatingBuy$19.00Medium
i
9/20/2019JMP SecuritiesInitiated CoverageOutperform$16.00High
i
8/7/2019OppenheimerSet Price TargetBuy$18.00High
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
2/26/2019OppenheimerSet Price TargetBuy$20.00Medium
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
11/26/2018Needham & Company LLCInitiated CoverageBuy ➝ Buy$23.00High
i
11/21/2018CIBCInitiated CoverageOutperform ➝ Outperform$15.00High
i
11/21/2018OppenheimerInitiated CoverageOutperform$15.00High
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
11/21/2018BMO Capital MarketsInitiated CoverageBuy$19.00High
i
11/20/2018Royal Bank of CanadaInitiated CoverageOutperform ➝ Outperform$20.00Low
i
(Data available from 4/21/2016 forward)
Gamida Cell logo
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that is in Phase III studies in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was founded in 1998 and is headquartered in Jerusalem, Israel.
Read More

Today's Range

Now: $7.38
$7.13
$7.47

50 Day Range

MA: $8.34
$7.27
$9.83

52 Week Range

Now: $7.38
$3.86
$15.00

Volume

221,937 shs

Average Volume

896,527 shs

Market Capitalization

$178.74 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.03

Frequently Asked Questions

What sell-side analysts currently cover shares of Gamida Cell?

The following Wall Street analysts have issued research reports on Gamida Cell in the last twelve months: Evercore ISI, HC Wainwright, Needham & Company LLC, Oppenheimer Holdings Inc., Piper Sandler, and Zacks Investment Research.
View the latest analyst ratings for GMDA.

What is the current price target for Gamida Cell?

4 Wall Street analysts have set twelve-month price targets for Gamida Cell in the last year. Their average twelve-month price target is $20.25, suggesting a possible upside of 174.4%. HC Wainwright has the highest price target set, predicting GMDA will reach $27.00 in the next twelve months. Needham & Company LLC has the lowest price target set, forecasting a price of $14.00 for Gamida Cell in the next year.
View the latest price targets for GMDA.

What is the current consensus analyst rating for Gamida Cell?

Gamida Cell currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe GMDA will outperform the market and that investors should add to their positions of Gamida Cell.
View the latest ratings for GMDA.

What other companies compete with Gamida Cell?

How do I contact Gamida Cell's investor relations team?

Gamida Cell's physical mailing address is 5 NAHUM HAFZADI STREET GIVAAT SHAUL, JERUSALEM L3, 91340. The company's listed phone number is 972-2659-5666 and its investor relations email address is [email protected] The official website for Gamida Cell is www.gamida-cell.com.